Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 24 (9), 2021-32

Antagonists of the Kappa Opioid Receptor

Affiliations
Review

Antagonists of the Kappa Opioid Receptor

Mariangela Urbano et al. Bioorg Med Chem Lett.

Abstract

The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress. Short-acting OPRK antagonists have been recently developed as a potential improvement over long-acting prototypic ligands including nor-BNI and JDTic. Remarkably the short-acting LY2456302 is undergoing phase II clinical trials for the augmentation of the antidepressant therapy in treatment-resistant depression. This Letter reviews relevant chemical and pharmacological advances in the identification and development of OPRK antagonists.

Keywords: Addictive disorders; Depression; OPRK antagonists; Short-acting; Stress-related disorders.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback